Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of...

Area of Science:

• Hematology
• Pediatric Medicine
• Coagulation Disorders

Background:

• Severe factor VII deficiency is a rare inherited bleeding disorder.
• Patients experience spontaneous, life-threatening hemorrhages.
• Prophylactic treatment is crucial for managing severe factor VII deficiency.

Observation:

• A pediatric patient with severe factor VII deficiency presented with frequent, spontaneous hemorrhages.
• The patient underwent several years of successful prophylactic treatment.
• Treatment involved every 3-day infusions of recombinant activated factor VII (rVIIa).

Findings:

• Recombinant activated factor VII (rVIIa) demonstrated successful long-term prophylaxis in this pediatric case.
• Multiple doses from a single reconstituted vial were used over 72 hours.
• This regimen effectively prevented severe bleeding episodes.

Implications:

• Long-term prophylactic use of rVIIa is a viable strategy for severe factor VII deficiency in children.
• This approach may offer an alternative to plasma-derived factor VII (PDVII) or prothrombin complex concentrate (PCC).
• Further research into rVIIa dosing and administration protocols for prophylaxis is warranted.